1 / 30

Results of Sentinel Sites Study

Results of Sentinel Sites Study. Dr Karin Denton. HPV testing as a triage for women with low grade cytological abnormalities: results from the sentinel sites studies. Kelly R, Patnick J, Kitchener HC, Moss SM Br J Cancer. 2011 Sep 27;105(7):983-8. Results.

fayola
Download Presentation

Results of Sentinel Sites Study

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Results of Sentinel Sites Study Dr Karin Denton

  2. HPV testing as a triage for women with low grade cytological abnormalities: results from the sentinel sites studies. Kelly R, Patnick J, Kitchener HC, Moss SM Br J Cancer. 2011 Sep 27;105(7):983-8.

  3. Results Study took place between 1 Jan 2008 and 1 April 2009 Data collected until September 2009 Analysis conducted independently at Cancer Screening Evaluation Unit, Institute of Cancer Research Over 90% of women attended colposcopy North Bristol NHS Trust/Avon Cervical screening programme

  4. HPV positive rates by age group and initial cytology result North Bristol NHS Trust/Avon Cervical screening programme

  5. SSS Results from different centresHPV positive rate by site and initial cytology 1 North Bristol NHS Trust/Avon Cervical screening programme

  6. SSS Results from different centresHPV positive rate by site and initial cytology 2 North Bristol NHS Trust/Avon Cervical screening programme

  7. Sentinel Site StudyResults at colposcopy *Includes 3 invasive cancers North Bristol NHS Trust/Avon Cervical screening programme

  8. Sentinel Site StudyPPV of colposcopy by site 1 North Bristol NHS Trust/Avon Cervical screening programme

  9. Sentinel Sites StudyRate of disease at 1, 2 3 and >3 years after negative colposcopy in 956 women with long term follow-up North Bristol NHS Trust/Avon Cervical screening programme

  10. Test of Cure • Preliminary data only in un-triaged women • 3203 women had test of cure • Failed test of cure by 18.3% • 6.2% by abnormal cytology • 12.1% by HPV +ve with normal cytology • Increased ‘failure’ rates with lower CIN grade • Persistent CIN2+ in 7% • 3% in HPV +ve • 13% in cytology +ve North Bristol NHS Trust/Avon Cervical screening programme

  11. Bristol experience

  12. Bristol Outcome Lletz histology for mild and borderline HPV positive smears with CIN 2/3 on PB(%)

  13. National outcomes • 90% attendance • Half had PB (47% negative histology) • 2.4% had LLETZ ( 28% neg histology) • 1/3 of identified CIN1 were not treated • Apparent overall cytological progression was 3.4% at 12 months

  14. Role for HPV testingTest of cure

  15. Management outcome in women referred to Colposcopy following HPV Test of Cure (TOC) Mohini Vachhani, Mary Brett*, Anne Vaughton, Vikki Finch, John Murdoch Colposopy Clinic and *Cellular Pathology Dept, Southmead Hospital Presented 22/06/2011 (Also, poster at BSCCP meeting 31.3-1.4/2011)

  16. Results • No of samples with HPV TOC test = 2369 • HPV negative = 2017 (85%) routine recall • HPV positive = 352 (15% - National rate18%) colposcopy • Referred to Southmead = 141 • Referred to St Michael’s = 211

  17. Outcome • TZ seen; NAD –> Cytology follow up in Community (n = 66) • TZ seen; abnormality seen (n = 22): 2 LLETZ (CIN 1, CIN2) 16 biopsy (3 CIN1, 13 neg) 4 rpt cytology (all negative)

  18. Outcome • Colposcopy was unsatisfactory in 30% of cases (i.e.TZ not seen): n = 38 • 6 had further LLETZ (all negative) • 13 had Bx (1 CIN 1, 12 neg)

  19. Outcome • Total no with repeat LLETZ = 8 cases • 7 had involved margins in index LLETZ • 2/8 with satisfactory colp and abnormality seen (Histo: CIN1, CIN2) • 6/8 with unsatisfactory colp (Histo: all negative)

  20. Conclusion • Women with positive TOC are at minimal risk of residual CIN (6/126 =4.8%) • 5/126 (4%) = CIN1 • 1/126 (0.8%) = CIN2 • Nationally PPV for CIN2 or worse = 2.9% and for CIN3 or worse = 0.4%

  21. Other studies H Kitchener et al. BJOG 2008, 15(8): 1001-1007 • Of cyto neg/HPV pos referrals to colp, 9/75 had CIN (at 6, 12 or 24 months follow up post-LLETZ; 4 CIN1, 4 CIN2, 1 CIN3) • = 12% treatment failure rate. (Compared with Southmead data: 6/126 had residual CIN = 4.8%)

  22. Changes to KC61? Don’t panic, no change to data collection or categories

  23. Longer term impact on KC61 data • BC rate will fall (due to loss of 2nd and 3rd bc) • Mild rate will also fall depending on previous policy • Will be visible effect from year 1 • High grade rate will also fall slightly because women will be referred on a prior low grade result

  24. PPV should remain unaffected

  25. Caution • You must decide on a diagnosis and stick to it regardless of HPV result • Do not use BC?HG in order to get an HPV test • Follow the management protocol

  26. ABC3 • ? Launch date • Will abolish BC?HG

  27. KEY TO CODES & ABBREVIATIONS Action codes • A routine recall • Rm early repeat in 'm' months • S suspend from recall PROVISIONAL Result codes • Ø * ?glandular neoplasia (non cervical) • G * ?glandular neoplasia (non cervical) (HPV tested) • 1 inadequate • 2 negative (not HPV tested) • N negative (HPV tested) • 3 low grade dyskaryosis (not HPV tested) • M low grade dyskaryosis (HPV tested) • 4 high grade dyskaryosis (severe) • 5 high grade dyskaryosis ?invasive squamous carcinoma • 6 ?glandular neoplasia of endocervical type • 7 high grade dyskaryosis (moderate) • 8 borderline change in squamous cells (not HPV tested) • B borderline change in squamous cells (HPV tested) • 9 borderline change in endocervical cells • E borderline change in endocervical cells (HPV tested)

  28. * non-cervical neoplasia treated as negative for CSP management • Infection codes • Ø (zero) HPV negative • 9 (nine) HPV positive • U HPV result inadequate/unreliable • Miscellaneous • NTDD Next Test Due Date • BLUE indicates codes used on NHAIS in format • Cytology result – HPV infection code – Action code • RED indicates manual action required to reset NTDD

  29. Questions?

More Related